sirolimus Supplier - Iris Biotech GmbH


Description :

Sirolimus inhibits angiogenesis - a new candidate for combination therapy!  Sirolimus, approved by the FDA for immunosuppression in transplant patients, is currently under investigation for cancer treatment.

Seller Info :

Iris Biotech GmbH

Product Details :

Cas Number53123-88-9

Categories :

About Suppliers :
Iris Biotech GmbH
IRIS Biotech is specialized in reagents for Peptide Synthesis, PEGylation, Life Science Research and Biocatalysis. uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X